基于癌症基因图集数据库与免疫组织化学方法分析SMARCB1对肝细胞癌早期诊断及预后的作用  

Effect of SMARCB1 on early diagnosis and prognosis of hepatocellular carcinoma

作　　者：王健[1] 张升敏[1] 吴佳勉 卢卓才[1] 杨建荣[1] 巫泓生[1] 陈浩[1] 林波[1] 许荣华[2] 曹天生[1] 

机构地区：[1]南方医科大学附属花都人民医院普外科,广东广州510800 [2]海南医学院附属医院肿瘤外科,海南海口570102

出　　处：《中国病理生理杂志》2017年第4期754-757,共4页Chinese Journal of Pathophysiology

基　　金：海南省自然科学基金资助项目(No.ZDXM2015080;No.309063);广州市花都区科技和信息化局项目(No.15-HDWS-012)

摘　　要：目的:通过研究SMARCB1在肝细胞癌(hepatocellular carcinoma,HCC)组织的表达,阐明其对HCC的早期诊断及预后的作用。方法:在癌症基因组图集(The Cancer Genome Atlas,TCGA)数据库中筛选出SMARCB1基因,运用免疫组织化学(immunohistochemistry,IHC)技术和TCGA分析SMARCB1在HCC组织和正常组织的表达情况,阐述其在HCC发生、发展进程中的作用。结果:IHC结果证实,与正常肝组织相比,HCC中SMARCB1的蛋白表达量显著上升(P<0.01)。IHC的结果显示SMARCB1的蛋白表达量与原发肿瘤分期呈正相关(P<0.05),即SMARCB1表达量越高,原发肿瘤分期越趋向晚期。TCGA的结果显示SMARCB1的高表达是HCC的独立预后因素(P<0.05)。结论:SMARCB1可能起着促癌基因的作用,临床上根据其在组织中的表达差异,可鉴别早期的HCC及良性组织,并可能有效地进行预后判断。AIM： To illuminate the effect of SWI/SNF-related,matrix-associated,actin-dependent regulator of chromatin,subfamily b,member 1（ SMARCB1） in early diagnosis and prognosis of hepatocellular carcinoma（ HCC） by determining the clinical expression of SMARCB1 in HCC tissue and benign liver tissue. METHODS： The specific target gene SMARCB1 was selected from these genes by using The Cancer Genome Atlas（ TCGA）. SMARCB1 expression in HCC tissue and benign liver tissue was measured by immunohistochemistry. Further statistical analysis of TCGA was performed to illuminate the role of SMARCB1 on HCC occurrence and progression. RESULTS： Compared with the benign liver tissue,immunohistochemical staining showed that SMARCB1 expression was significantly up-regulated in the HCC tissue（ P〈0. 01）. In addition,SMARCB1 expression was significantly associated with advanced tumor stage（ P〈0. 05）. The relation between SMARCB1 expression at mRNA level and clinical prognosis was analyzed. The results indicated that high SMARCB1 expression was an independent prognostic factor for HCC（ P〈0. 05）. CONCLUSION： SMARCB1 may play a part as a carcinogenic gene in tumorigenesis. We can distinguish primary HCC samples from non-malignant samples according to its different clinical expression. High SMARCB1 expression probably predicts poor outcome in HCC patients.

关 键 词：肝细胞癌 SMARCB1 诊断 预后 

分 类 号：R730.23[医药卫生—肿瘤]